Acute Pancreatitis and Thrombosis (PATHRO)

Study Overview
=================
Brief Summary
-----------------
Severe acute pancreatitis (AP) is a pathology with high morbidity and mortality. Portosplenomesenteric vein thrombosis is a well-known local complication of AP with a variable incidence, which can reach up to 50% in case of severe AP. However, there is no specific recommendation regarding the management of Portosplenomesenteric vein thrombosis. By analogy to all venous thrombosis, the European Society of Gastroenterology recommends curative anticoagulation. However, the efficacy of curative anticoagulation has never been evaluated by prospective studies. In addition, bleeding complications during AP occur in approximately 10% of patients and are associated with a poor prognosis. The investigators wish to conduct an observational multi-center study with epidemiologic aims, including all patients admitted for AP and with a diagnosis of portosplenomesenteric vein thrombosis. The aim of this study is to evaluate the therapeutic management of these patients, the efficacy and safety of anticoagulant treatment for the treatment of Portosplenomesenteric vein thrombosis, and their outcomes.

Detailed Description
-----------------
The investigators will include prospectively all patients admitted for AP with a computed tomography diagnosis of portosplenomesenteric vein thrombosis.

Official Title
-----------------
Management of Portoplenomesenteric Vein Thrombosis in Patients With Acute Pancreatitis : an Observational Study

Conditions
-----------------
Acute Necrotizing Pancreatitis, Portosplenomesenteric Venous Thrombosis

Intervention / Treatment
-----------------
* Other: observational study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Patients (age > 18 years) with acute pancreatitis AND a diagnosis on CT injected with portal time of portosplenomesenteric vein thrombosis or laminated veins (without passage of blood flow through the vessel but without visible intraluminal thrombus) will be included. Exclusion Criteria: Patient under guardianship Refusal to participate in research Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: observational study|patients admitted for AP with portosplenomesenteric vein thrombosis.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of anticoagulation therapy | incidence defined as : the ratio of the number of patients on curative anticoagulant therapy to the number of patients admitted with AP and portosplenomesenteric vein thrombosis during the inclusion period | up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate the outcomes of Number of patients admitted for AP with portosplenomesenteric vein thrombosis |  | up to 12 months | 
| hospital mortality at D28 | evaluate the hospitality mortality at D28 of patients admitted for AP with portosplenomesenteric vein | Day 28 | 
| hospital mortality at D90 | evaluate the hospitality mortality at D90 of patients admitted for AP with portosplenomesenteric vein | Day 90 | 
| hospital mortality at 6 months | evaluate the hospitality mortality at 6 months of patients admitted for AP with portosplenomesenteric vein | 6 months | 
| hospital mortality at 12 months | evaluate the hospitality mortality at 12 months of patients admitted for AP with portosplenomesenteric vein | 12 months | 
| incidence of portal cavernoma | evaluate the incidence of portal cavernoma of patients admitted for AP with portosplenomesenteric vein | up to 12 months | 
| incidence of type 2 diabetes secondary to AP | evaluate the incidence of type 2 diabetes secondary to AP of patients admitted for AP with portosplenomesenteric vein | up to 12 months | 
| incidence of occurrence of malabsorption | evaluate the incidence of occurrence of malabsorption of patients admitted for AP with portosplenomesenteric vein | up to 12 months | 
| incidence of digestive ischemia | evaluate the incidence of digestive ischemia of patients admitted for AP with portosplenomesenteric vein | up to 12 months | 
| incidence of hepatic ischemia | evaluate the incidence of hepatic ischemia of patients admitted for AP with portosplenomesenteric vein | up to 12 months | 
| incidence of pancreatic necrosis | evaluate the incidence of pancreatic necrosis of patients admitted for AP with portosplenomesenteric vein | up to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anticoagulation, acute necrotizing pancreatitis, acute pancreatitis, pancreas disease, anticolagulant therapy, bleeding, Portosplenomesenteric Vein Thrombosis, splanchic venous thrombosis